- cafead Sep 09, 2020 at 08:22: PM
via Last month, Roche’s Tecentriq chalked up a surprising failure when used in tandem with chemotherapy paclitaxel in triple negative breast cancer (TNBC). The FDA has taken notice, issuing a warning that might spell trouble for a conditional nod of the PD-L1 agent.
On Tuesday, the FDA alerted the public that the Tecentriq-paclitaxel combo didn’t work in a clinical trial in previously untreated locally advanced or metastatic TNBC and warned doctors not to use it.
article source
On Tuesday, the FDA alerted the public that the Tecentriq-paclitaxel combo didn’t work in a clinical trial in previously untreated locally advanced or metastatic TNBC and warned doctors not to use it.
article source